Modality
Nanobody
MOA
KRASG12Ci
Target
FXIa
Pathway
JAK/STAT
Heart FailureSCLC
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
~Jul 2020
→ ~Oct 2021
Phase 2
Jan 2022
→ Sep 2025
Phase 2Current
NCT08534549
2,320 pts·Heart Failure
2022-01→2025-09·Active
2,320 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-09-166mo agoPh2 Data· Heart Failure
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2
Active
Catalysts
Ph2 Data
2025-09-16 · 6mo ago
Heart Failure
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08534549 | Phase 2 | Heart Failure | Active | 2320 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Lisolucimab | Novartis | Approved | CD20 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| BII-5449 | Biogen | Phase 3 | FXIa |